Discover investment opportunities in Neuroscience Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Neuroscience Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Neuroscience Stocks using our Smart AI Filter.
8 stocks found for "Neuroscience Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.55 | ±32.2% | 10.6 | 0.00% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.60 | ±39.2% | 20.8 | 0.00% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
1.21 | ±56.0% | -13.3 | 0.00% | |||
0.34 | ±25.2% | 8.0 | 0.00% | |||
1.95 | ±75.5% | -1.5 | 0.00% | |||
0.93 | ±47.7% | 25.5 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What makes VRTX and BIIB stocks appealing to neuroscience investors?
A: VRTX (Vertex Pharmaceuticals) and BIIB (Biogen) are key players in neuroscience due to their focus on treating neurological and genetic disorders. Their pipelines include innovative therapies targeting diseases like cystic fibrosis and Alzheimer's. Investors may find appeal in their strong R&D capabilities and market potential for breakthrough treatments.
Q: How do REGN's therapies potentially impact its stock performance during market fluctuations?
A: REGN (Regeneron Pharmaceuticals) develops biologics that command premium pricing, which may buffer it during economic downturns. Its innovations in immunology and a strong pipeline, including treatments for eye diseases and cancer, contribute to less volatility and potential for stable performance.
Q: Are SAGE and MRNS considered growth stocks within the neuroscience industry?
A: SAGE (Sage Therapeutics) and MRNS (Marinus Pharmaceuticals) focus on innovative treatments for central nervous system disorders. Many investors see them as growth stocks due to their developing therapies for depression and epilepsy, which have high unmet medical needs, suggesting potential for revenue growth.
Q: How do ACAD and NBIX contribute to the diversity of neuroscience stocks?
A: ACAD (Acadia Pharmaceuticals) and NBIX (Neurocrine Biosciences) enhance diversity in the neuroscience sector through their specialization in different diseases. ACAD focuses on psychosis and dementia-related conditions, while NBIX targets movement disorders, reflecting a broad range of potential therapeutic applications.
Q: What role does ALNY play in advancing RNAi therapeutics within neuroscience?
A: ALNY (Alnylam Pharmaceuticals) is a leading company in RNA interference (RNAi) therapeutics, which offers a novel approach to treating genetic disorders. Its advancements in RNAi address previously undruggable targets, providing a unique competitive edge in the neuroscience pipeline and attracting interest for innovation-focused investors.
Q: Why might IONS appeal to dividend-focused investors in the biotechnology sector?
A: IONS (Ionis Pharmaceuticals) is primarily known for its antisense oligonucleotide drug development. While it primarily reinvests earnings into R&D, some investors are drawn to its potential for strategic partnerships and licensing deals, which can result in sporadic cash influxes beneficial for dividends.
PTC Therapeutics PTCT is currently in the final 18th phase of its Adhishthana cycle on the weekly chart, and the outlook remains bleak. Signals point to prolonged underperformance, with weakness likely to last through 2030.
Read moreInvestors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors a better bang for their buck right now?
Read more